1292300-75-4

Usage

Uses

Used in Pharmaceutical Industry:
TASP0415914 is used as an anti-HIV agent for its ability to inhibit the HIV-1 reverse transcriptase enzyme, which is essential for the virus's replication. This makes it a potential therapeutic agent for the treatment of HIV infection.
Used in HIV Research:
In the field of HIV research, TASP0415914 is utilized for studying the mechanisms of HIV replication and for identifying potential targets for antiretroviral therapy. Its high specificity and potency in inhibiting the reverse transcriptase enzyme provide valuable insights into the development of new treatments for HIV-1.
Used in Drug Development:
TASP0415914 is employed in the development of new antiretroviral drugs, given its demonstrated effectiveness against HIV-1 in preclinical studies. Its unique mechanism of action could lead to the creation of novel therapeutics that offer improved efficacy and reduced side effects compared to existing treatments.
Used in Combination Therapies:
TASP0415914 may also be used in combination with other antiretroviral drugs to enhance the overall effectiveness of HIV treatment. Its high specificity for the reverse transcriptase enzyme could potentially allow for synergistic effects when used alongside other compounds that target different aspects of the viral life cycle.

Upstream product

• 67899-00-7 2-amino-4-methyl-thiazole-5-carboxylic acid 
• 63788-62-5 2-(acetylamino)-4-methyl-1,3-thiazole-5-carboxylic acid 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 7210-76-6 ethyl-2-amino-4-methylthiazole-5-carboxylate 
• 89122-73-6 3-acetoxypiperidine 

Relevant academic research and scientific papers

Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4- methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases

Class I phosphoinositide 3-kinases (PI3Ks), particularly PI3Kγ, have become attractive drug targets for inflammatory and autoimmune disorders such as rheumatoid arthritis. Herein, we describe the synthesis and the structure-activity relationships (SAR) of a series of 2-amino-5-oxadiazolyl thiazoles, culminating in the identification of 8j (TASP0415914), an orally potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ). TASP0415914 demonstrated good potency in a cell-based assay and, furthermore, exhibited in vivo efficacy in a collagen induced arthritis (CIA) model in mice after oral administration.

AMINOTHIAZOLE DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase 3 inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn''s disease, irritable colitis, Sjoegren''s syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.